Lipella Pharmaceuticals Files Proxy Statement for Annual Meeting

TL;DR

Lipella Pharma (LIPF) proxy filed - annual meeting Sept 10. Vote your shares!

AI Summary

Lipella Pharmaceuticals Inc. filed a definitive proxy statement (DEF 14A) on August 12, 2024, for its annual meeting on September 10, 2024. The filing concerns the solicitation of proxies for the meeting, which will include the election of directors and other corporate matters. The company is based in Pittsburgh, PA, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with crucial information regarding the company's governance and upcoming decisions, including director elections, which can impact the company's strategic direction and performance.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and shareholder votes can introduce uncertainty regarding corporate governance and future strategy.

Key Numbers

• DEF 14A — Filing Type (Definitive Proxy Statement)

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• 0001347242 (company) — Central Index Key
• 20240910 (date) — Annual Meeting Date
• 20240812 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — Company’s common stock, par value $0.0001 per share (the “Common Stock&rdqu
• $0.77 — of Common Stock at prices ranging from $0.77 to $5.00 per share. 9 (5) Number o
• $5.00 — n Stock at prices ranging from $0.77 to $5.00 per share. 9 (5) Number of shares
• $2.19 — n Stock at prices ranging from $0.77 to $2.19 per share. (7) Number of shares of C

Filing Documents

• g084383_sch14a.htm (DEF 14A) — 467KB
• img001.jpg (GRAPHIC) — 9KB
• img002.jpg (GRAPHIC) — 7KB
• 0001753926-24-001391.txt ( ) — 491KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 9 ELECTION OF DIRECTORS (Proposal No. 1) 11 Vote Required and Recommendation 13 CORPORATE GOVERNANCE 14 Board of Directors 14 Director Independence 14 Board Composition and Diversity 14 Board Meetings and Attendance 15 Annual Meeting Attendance 15 Stockholder Communications with the Board 15 Board Committees 15 Family Relationships 17 Involvement in Certain Legal Proceedings 17 Leadership Structure of the Board 17 Risk Oversight 17 Insider Trading Arrangements and Policies 17 Information About Our Executive Officers 18 Delinquent Section 16(a) Reports 19 DIRECTOR COMPENSATION 20 EXECUTIVE OFFICER COMPENSATION 21 Summary Compensation Table for Fiscal Years 2023 and 2022 21 Employment Agreements 22 Other Compensation 23 Outstanding Equity Awards as of December 31, 2023 23 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 26 AUDIT COMMITTEE REPORT 27 AUTHORIZATION OF THE BOARD TO AMEND THE CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF ALL OUTSTANDING SHARES OF COMMON STOCK (Proposal No. 2) 28 Summary 28 Board Requirement to Implement the Reverse Stock Split 29 Effective Date 29 Purposes of the Reverse Stock Split 29 Risks of the Reverse Stock Split 30 Principal Effects of the Reverse Stock Split 31 Fractional Shares 33 No Dissenters’ Rights 33 Certain United States Federal Income Tax Consequences 33 Accounting Consequences 34 Exchange of Stock Certificates 34 Book-Entry 35 Interests of Directors and Executive Officers 35 Vote Required and Recommendation 35 4 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS (Proposal No. 3) 37 Fees Paid to Independent Registered Public Accounting Firm 37 Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered

View Full Filing

View this DEF 14A filing on SEC EDGAR